Compare Msci Inc (MSCI) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Tempus AI — how do they compare? Msci Inc trades at $554.53 (market cap $40.32B), while Tempus AI trades at $60.36 (market cap $11.13B). The key difference: Msci Inc is far larger — about 3.6× Tempus AI's market cap, and Msci Inc pays a 1.48% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| MSCI | TEM | |
|---|---|---|
Market Cap | $40.32B | $11.13B |
Sector | Financials | Broad Market / Factor |
52-Week High | $643.83 | $103.25 |
52-Week Low | $511.84 | $41.55 |
Enterprise Value | $46.48B | $11.75B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $551.39, down 3.77% over 24 hours, amid a bearish technical signal. The stock shows strong fundamentals with revenue growth to $3.13B in 2025 and a net income margin of 40.73%, though it faces a high P/E of 30.32. Recent developments include the acquisition of First Street and a strategic partnership with UBS, enhancing its private markets platform. Cash flow turned positive in 2025, but high debt levels and a negative equity position pose risks.
The outlook is mixed: analyst consensus is bullish with a $728.14 price target, but technical indicators signal caution. Upside potential hinges on continued earnings beats and revenue growth, while risks include market volatility and execution challenges. Investors should weigh strong profitability against valuation concerns and debt load.
Tempus AI (TEM) trades at $64.29, down 0.51% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. The company reported a net loss of $245.03M in 2025 despite revenue of $1.27B, but recent quarterly EPS beats and FDA clearance for an AI-enabled ECG product (Business Wire, 2026-08-24) highlight growth potential in precision medicine. Analyst consensus is strongly bullish with a $69.20 price target.
Outlook: TEM's AI-driven healthcare platform positions it for long-term growth amid industry shifts toward personalized medicine, though persistent losses and high P/B of 25.01 pose valuation risks. Near-term catalysts include continued execution on recent contracts and pipeline developments, but investors face volatility from cash burn and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
